Table 3.
Frequency of patients with nodules harboring multiple coexisting strong and/or weak drivers among patients with nodules harboring mutations and fusions that underwent focused (N = 931, green) or expanded (N = 1152, blue) mutation panel testing [Color table can be viewed at http://wileyonlinelibrary.com]
| Focused panel N = 931 (N%) | Expanded panel N = 1135 (N%) | |
|---|---|---|
| Coexisting strong drivers | ||
| BRAF(V600E), TERT | NA | 1.1% (12) |
| Coexisting strong and weak drivers | ||
| BRAFV600E, BRAF X* | 0.1% (1) | 0% |
| BRAFV600E, RAS | 0.5% (5) | 0% |
| BRAFV600E, PIK3CA | 0% | 0.1% (1) |
| TERT, PIK3CA | NA | 0.1% (1) |
| TERT, RAS | NA | 3.2% (36) |
| TERT, BRAF X* | NA | 0.1% (1) |
| RET, RAS | NA | 0.1% (1) |
| Coexisting weak drivers | ||
| RAS, PPARG fusion | 0.1% (1) | 0% |
| PIK3CA, RAS | 0.2% (2) | 0.2% (2) |
| PTEN, RAS | NA | 0.1% (1) |
| PTEN, GNAS | NA | 0.2% (2) |
| Total coexisting drivers | 1% (9) | 5% (57) |
| P value | P < .001 | |
Notes: NA, not applicable as both mutations were not tested for in focused panel; BRAF X*, mutations in BRAF other than BRAFV600E.